<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423045</url>
  </required_header>
  <id_info>
    <org_study_id>UCONC</org_study_id>
    <nct_id>NCT01423045</nct_id>
  </id_info>
  <brief_title>Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease</brief_title>
  <official_title>Association Between Urine Concentration Ability and the Progression of Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benaya Rozen-Zvi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that urine concentrating ability can predict the rate of kidney&#xD;
      function decline.&#xD;
&#xD;
      Patients with kidney disease at the investigatorsclinic will be asked to give first morning&#xD;
      urine sample and osmolarity will be measured. The investigators will follow up kidney&#xD;
      function decline and check if there is association with urine osmolarity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design:&#xD;
&#xD;
      Prospective observational study&#xD;
&#xD;
      Setting:&#xD;
&#xD;
      Predialysis clinic.&#xD;
&#xD;
      Participants:&#xD;
&#xD;
      We will include adults &gt;18 years providing signed informed consent.&#xD;
&#xD;
      Inclusion:&#xD;
&#xD;
      Patients with CKD and estimated GFR of less then 50 mL per minute estimated by the short MDRD&#xD;
      equation base on two creatinine values taken at least two weeks apart and are not getting&#xD;
      steroids or immunosuppressive medication as treatment for their primary kidney disease.&#xD;
&#xD;
      Exclusion:&#xD;
&#xD;
        1. Life expectancy of less then 6 month.&#xD;
&#xD;
        2. Expected to start renal replacement therapy within 3 month.&#xD;
&#xD;
        3. Acute or acute on chronic renal failure with reversible component.&#xD;
&#xD;
        4. Treatment with AVP inhibitors.&#xD;
&#xD;
        5. Chronic hyponatremia (Na+&lt;135 in two measurement two weeks apart).&#xD;
&#xD;
        6. Primary polydipsia.&#xD;
&#xD;
        7. Inability to give informed consent.&#xD;
&#xD;
        8. Clinical hypovolemia.&#xD;
&#xD;
      Outcomes:&#xD;
&#xD;
      Primary outcomes:&#xD;
&#xD;
      Rate of GFR decline as assessed by short MDRD equation with at least three measurements at&#xD;
      least three month apart.&#xD;
&#xD;
      . Secondary efficacy&#xD;
&#xD;
        1. Rate of ESKD define as need RRT.&#xD;
&#xD;
        2. Overall mortality.&#xD;
&#xD;
        3. ESKD and overall mortality.&#xD;
&#xD;
        4. Blood pressure as assessed by clinic measurement.&#xD;
&#xD;
        5. Protein creatinine ratio in random urine sample.&#xD;
&#xD;
        6. Hemoglobin level.&#xD;
&#xD;
        7. Need for erythropoietin treatment.&#xD;
&#xD;
        8. Blood level of 25OH vitamin D and 1,25OH vitamin D.&#xD;
&#xD;
        9. PTH, calcium and phosphate level.&#xD;
&#xD;
       10. The occurrence of edema by physical evaluation.&#xD;
&#xD;
      Predefined subgroup analysis:&#xD;
&#xD;
        1. Diabetic patients.&#xD;
&#xD;
        2. Patients treated with diuretics.&#xD;
&#xD;
      Sample size:&#xD;
&#xD;
      We will need to recruit about 200 patients.&#xD;
&#xD;
      Statistical methods:&#xD;
&#xD;
      We will use linear regression analysis with 95% CI for the continuous variable. And chi&#xD;
      square for dichotomous variable.&#xD;
&#xD;
      Data collection and trial flow:&#xD;
&#xD;
      All patients in predialysis clinic of Dan district of &quot;Kupat holim clalit&quot; will be screen.&#xD;
      Patients fulfilling inclusion criteria will be approached by trial investigator for informed&#xD;
      consent and trial recruitment. For patients fulfilling inclusion criteria that will not&#xD;
      consent to participate we will be record name and ID without further details. Consenting&#xD;
      patients will bring the three samples of first voided urine of the morning for osmolarity,&#xD;
      PH, sodium, potassium and chloride.&#xD;
&#xD;
      Patient recruitment:&#xD;
&#xD;
      Baseline data collection:&#xD;
&#xD;
      Collection of data will include baseline conditions, primary kidney disease, current&#xD;
      medications, clinical evaluation for edema and blood pressure.&#xD;
&#xD;
      Laboratory results will include creatinine, urea, sodium, potassium, GFR assessed by short&#xD;
      MDRD equation, protein creatinine ratio in random urine sample Hb level, vitamin D level&#xD;
      calcium, phosphorus and PTH.&#xD;
&#xD;
      Follow-up and outcome data collection:&#xD;
&#xD;
        1. Creatinine, estimated GFR, urea, sodium, potassium chloride, hemoglobin and protein&#xD;
           creatinine ratio in random urine sample at least every three month&#xD;
&#xD;
        2. Clinical assessment for edema and blood pressure ant least every three month.&#xD;
&#xD;
        3. Time to initiation of dialysis or transplantation.&#xD;
&#xD;
        4. Mortality of any cause and cardiovascular mortality.&#xD;
&#xD;
        5. Hospitalization for any cause and the length of hospital stay.&#xD;
&#xD;
        6. The need for ESA treatment and ESA dose will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>eGFR slope</measure>
    <time_frame>12 month</time_frame>
    <description>Creatinnie value will be measured at least every three month and eGFR will be calculated by MDRD equation. A regression line will be plotted against time and the eGFR slope will be calculated.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CKD and estimated GFR of less then 50 mL per minute.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with CKD and estimated GFR of less then 50 mL per minute estimated by the&#xD;
             short MDRD equation base on two creatinine values taken at least two weeks apart and&#xD;
             are not getting steroids or immunosuppressive medication as treatment for their&#xD;
             primary kidney disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Life expectancy of less then 6 month.&#xD;
&#xD;
          2. Expected to start renal replacement therapy within 3 month.&#xD;
&#xD;
          3. Acute or acute on chronic renal failure with reversible component.&#xD;
&#xD;
          4. Treatment with AVP inhibitors.&#xD;
&#xD;
          5. Chronic hyponatremia (Na+&lt;135 in two measurement two weeks apart).&#xD;
&#xD;
          6. Primary polydipsia.&#xD;
&#xD;
          7. Inability to give informed consent.&#xD;
&#xD;
          8. Clinical hypovolemia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benaya Rozen-Zvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General health services - Dan Petach tiqua county</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pre dialysis clinic Dan Petach Tiqua county General health service</name>
      <address>
        <city>Ganey Tiqua</city>
        <zip>55900</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Benaya Rozen-zvi, MD</last_name>
      <phone>050-8773766</phone>
      <email>benayarz@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Boris Zingerman, MD</last_name>
      <phone>050-6260428</phone>
      <email>borisz@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <last_update_submitted>August 24, 2011</last_update_submitted>
  <last_update_submitted_qc>August 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Meir Medical Center</investigator_affiliation>
    <investigator_full_name>Benaya Rozen-Zvi</investigator_full_name>
    <investigator_title>attending nephrologist pre dialysis clinic Dan petach-tiqua county</investigator_title>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Urine osmolarity</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

